This trial has been completed.

Condition st-elevation myocardial infarction
Treatments mineralocorticoid receptor antagonist potassium-canrenoate, placebo
Phase phase 3
Sponsor University College, London
Collaborator British Heart Foundation
Start date November 2013
End date May 2016
Trial size 61 participants
Trial identifier NCT01882179, 12/0533


Heart attacks, or myocardial infarcts, are a major cause of death and disability in the UK. Immediate unblocking of the obstructed heart vessel with a balloon catheter and implantation of a mesh scaffold (stent) in heart centers is warranted in these patients. Morbidity and mortality in this patient group is related to the infarct size. Therefore, there is a need to discover novel therapeutic agents which reduce myocardial infarct size and preserve the contractile heart function.

Large trials involving several thousand patients have demonstrated a survival benefit in patients with impaired heart function due to a heart attack, who received a mineralo-corticoid receptor antagonist (MRA, drug name: spironolactone). In these trials patients received the drug late, 3-14 days after the heart attack.

Our proposal is to investigate whether MRA therapy administered intravenously prior to unblocking an occluded heart vessel, can reduce infarct size and as such can prevent long term sequelae of heart attacks.

150 patients admitted to 4 tertiary care hospitals (Heart Hospital London, London Chest, Essex Cardiothoracic Center and Leeds General Infirmary) for heart attack will be randomly assigned to receive MRA treatment or placebo. The first dose of the MRA will be applied intravenously immediately in the catheter suite, even before re-opening of the occluded vessel. From the second day on, patients will be prescribed oral MRA treatment, as a pill, for a total of three months. Before hospital discharge and after three months, a magnetic resonance image (MRI) of the heart will accurately investigate the evolution of infarct (scar) size and the contractile heart function and compare the group of patients who received the MRA drug versus the placebo control group. Of note, patients with an ejection fraction <40% AND signs of heart failure OR diabetes will go on open label eplerenone according to current guidelines, instead of the study drug.

This study will give first evidence, if very early MRA treatment improves heart function and should be used as early as possible for treatment of patients after a heart attack.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator, outcomes assessor)
Primary purpose treatment
(Placebo Comparator)
Intravenous saline bolus prior to PPCI followed by oral placebo for 3 months
(Active Comparator)
1st dose (day 0) given i.v. (potassium-canrenoate), before primary PCI day 1 - 12 weeks: spironolactone 25mg daily, which is uptitrated to 50mg daily after 2 weeks, if possible In case the LVEF <40% on baseline MRI and the patient shows signs of heart failure or is diabetic, the patient will receive open label eplerenone instead of the study drug, according to current guidelines.
mineralocorticoid receptor antagonist potassium-canrenoate

Primary Outcomes

Myocardial infarct (MI) size, as assessed by cardiac magnetic resonance imaging
time frame: 12 weeks after STEMI

Secondary Outcomes

Markers of myocardial reperfusion injury
time frame: 48 hours
Microvascular obstruction on cardiac MRI
time frame: 1-3 days after STEMI
Myocardial salvage
time frame: 12 weeks
Acute myocardial infarct size
time frame: 1-3 days
LV remodelling
time frame: 12 week cardiac MRI scan
Clinical outcome measures
time frame: 12 weeks

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: Inclusion criteria for entry into trial - Patients >18 years - Patients presenting with acute STEMI (as assessed by 12 lead ECG; ST segment elevation ≥2 mm (0.2 mV) in 2 or more contiguous precordial leads or ≥1mm (0.1mm) in 2 or more adjacent limb leads). - Presentation within 12 hours after symptom onset Inclusion criteria for randomization (assessed in catheter laboratory) - Angiographically proven proximal occlusion (TIMI 0) of a major coronary vessel (LAD, LCX, RCA). - Normal potassium (<5.0 mmol/l) Exclusion Criteria: - Patients with known LVEF ≤40% - Participation in another trial - Cardiogenic shock (positive shock index OR need for catecholamine support OR systolic blood pressure < 90 mmHg) - Killip class > 2 - Prior myocardial infarction - Known compromised renal function (eGFR < 30 ml/min/1.73 m2) or potassium > 5.0 mmol/l - Current treatment with mineralocorticoid receptor antagonists - Pregnant or lactating females - Allergies to IMP or its excipients - Known contraindication to cardiac magnetic resonance imaging (MRI) such as significant claustrophobia, severe allergy to gadolinium chelate contrast, , presence of MRI contraindicated implanted devices (eg, pacemaker, implanted cardiac defibrillator, cardiac resynchronization therapy device, cochlear implant), imbedded metal objects (eg, shrapnel), or any other contraindication for cardiac MRI.

Additional Information

Official title MINeralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (STEMI)
Principal investigator Pascal Meier, MD
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by University College, London.